MoonLake Immunotherapeutics AG: Clinical Trials

10 trials sponsored by MoonLake Immunotherapeutics AG, newest first
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 active not recruiting, 2 enrolling by invitation. 7 Phase 3, 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 37Active not recruiting 3, Completed 2, Enrolling by invitation 2
Phase 22Completed 2
Phase 11Completed 1

Follow MoonLake Immunotherapeutics AG: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Sonelokimab - Arthritis, Psoriatic		Phase 3Enrolling by invitationMoonLake Immunotherapeutics AG15602025-11-132026-09-09
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
Sonelokimab - Hidradenitis Suppurativa		Phase 3Enrolling by invitationMoonLake Immunotherapeutics AG8352025-06-272026-06-08
An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector
Sonelokimab - Relative Bioequivalence		Phase 1CompletedMoonLake Immunotherapeutics AG1202025-06-052025-12-09
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
Sonelokimab - Hidradenitis Suppurativa		Phase 3Active not recruitingMoonLake Immunotherapeutics AG352024-12-302026-05-06
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Sonelokimab, Placebo, Risankizumab - Arthritis, Psoriatic		Phase 3Active not recruitingMoonLake Immunotherapeutics AG6002024-10-152026-10-09
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
Sonelokimab, Placebo - Arthritis, Psoriatic		Phase 3Active not recruitingMoonLake Immunotherapeutics AG9602024-10-152026-10-09
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sonelokimab, Placebo - Hidradenitis Suppurativa		Phase 3CompletedMoonLake Immunotherapeutics AG4222024-05-152026-08-12
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sonelokimab, Placebo - Hidradenitis Suppurativa		Phase 3CompletedMoonLake Immunotherapeutics AG4182024-05-142026-06-08
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
Sonelokimab, Placebo, Adalimumab - Arthritis, Psoriatic		Phase 2CompletedMoonLake Immunotherapeutics AG2072022-12-132026-09-10
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Sonelokimab (M1095), Adalimumab, Placebo - Hidradenitis Suppurativa		Phase 2CompletedMoonLake Immunotherapeutics AG2342022-04-252026-09-09

Conditions studied

Skin Diseases (6)  ·  Hidradenitis (5)  ·  Hidradenitis Suppurativa (5)  ·  Skin Diseases, Bacterial (5)  ·  Suppuration (5)  ·  Sweat Gland Diseases (5)  ·  Arthritis, Psoriatic (4)  ·  Arthritis (1)  ·  Folliculitis (1)  ·  Joint Diseases (1)  ·  Psoriasis (1)

Interventions

sonelokimab (10)  ·  Adalimumab (2)  ·  risankizumab (1)

Countries

United States (9)  ·  Bulgaria (7)  ·  Germany (7)  ·  Poland (7)  ·  Canada (6)  ·  Czechia (5)  ·  Hungary (5)  ·  Spain (5)  ·  France (4)  ·  United Kingdom (4)  ·  Netherlands (3)  ·  Portugal (3)  ·  Slovakia (3)  ·  Belgium (2)  ·  Estonia (2)

Top investigators

Prof Kristian Reich, M.D., Ph.D. (equ.) (2)

Results publications

PMID 41053449